172.36 USD
+0.04 (+0.02%)
172.4 USD
+0.04 (+0.02%)
ChartMill assigns a Buy % Consensus number of 53% to RETA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 175.9. This target is 2.05% above the current price.
RETA was analyzed by 15 analysts. The buy percentage consensus is at 53. So analysts seem to be rather neutral about RETA.
In the last month the buy percentage fell by 17 points. So the trust of analysts is decreasing.
RETA was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-08-15 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2023-08-01 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2023-08-01 | Citigroup | Downgrade | Buy -> Neutral |
| 2023-07-31 | Ladenburg Thalmann | Downgrade | Buy -> Neutral |
| 2023-07-31 | Baird | Maintains | Outperform -> Outperform |
| 2023-07-31 | Jefferies | Downgrade | Buy -> Hold |
| 2023-07-28 | Stifel | Downgrade | Buy -> Hold |
| 2023-07-24 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-07-06 | TD Cowen | Initiate | Outperform |
| 2023-06-29 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2023-06-28 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-06-28 | Barclays | Maintains | Overweight -> Overweight |
| 2023-06-12 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2023-05-11 | Barclays | Maintains | Overweight -> Overweight |
| 2023-04-13 | Stifel | Maintains | Buy |
| 2023-03-27 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-03-01 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-03-01 | Barclays | Maintains | Overweight |
| 2023-03-01 | Baird | Maintains | Neutral |
| 2023-03-01 | Goldman Sachs | Maintains | Buy |
| 2023-03-01 | Citigroup | Maintains | Buy |
| 2023-02-24 | Goldman Sachs | Maintains | Buy |
| 2022-11-28 | Goldman Sachs | Maintains | Buy |
| 2022-11-09 | Barclays | Maintains | Overweight |
| 2022-11-09 | Goldman Sachs | Maintains | Buy |
| 2022-11-09 | Citigroup | Maintains | Buy |
| 2022-10-19 | Guggenheim | Initiate | Buy |
| 2022-08-09 | Baird | Maintains | Neutral |
| 2022-05-27 | Citigroup | Maintains | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
REATA PHARMACEUTICALS INC-A / RETA FAQ
Can you provide the average price target for REATA PHARMACEUTICALS INC-A stock?
15 analysts have analysed RETA and the average price target is 175.9 USD. This implies a price increase of 2.05% is expected in the next year compared to the current price of 172.36.
What is the consensus rating for RETA stock?
The consensus rating for REATA PHARMACEUTICALS INC-A (RETA) is 53.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.